A new form of Metrodin (highly purified) characterized by the absence
of any urinary protein contaminants and by a high specific activity, h
as been recently obtained through additionnal immunoextraction and chr
omatographic procedures. The respect of its main physico-chemical char
acteristics and the very low LH activity justify that the pharmacokine
tics and the clinical efficacy of this new form are identical to those
of the classical Metrodin. In a clinical point of view, Metrodin HP c
ombines the double advantage of an excellent local and general toleran
ce (without any allergic side effect) and of a subcutaneous route of i
njection which allows a self-administration by the patient.